This recognition prompted trials of combined IGF-1R:EGFR inhibition, alone or with standard cancer treatments

This recognition prompted trials of combined IGF-1R:EGFR inhibition, alone or with standard cancer treatments. to identify features distinguishing the tumors and sponsor environment of responders from non-responders. We emphasize the importance of incorporating biospecimen collection into trial design, and wording patient consents to allow post hoc analysis of trial material as fresh data become available….